Diabetic Cardiovascular Complications R&D Services
Cardiovascular complications of diabetes are the leading cause of death in diabetic individuals, characterized by complex pathological mechanisms and significant challenges in clinical translation. Ace Therapeutics focuses on addressing key R&D challenges in this field, offering integrated preclinical services ranging from pathological analysis and animal modeling to therapy translation and diagnostic technology implementation. We are committed to leveraging our customized disease models and advanced technology platforms to help clients accelerate the development of innovative targets, therapeutics, and diagnostic products.
Key Challenges in Drug Development for Diabetic Cardiovascular Complications
Diabetic cardiovascular complications (including diabetic cardiomyopathy, coronary heart disease, heart failure, peripheral artery disease, etc.) are the leading cause of death among individuals with diabetes. Their pathophysiology is complex, involving the interplay of multiple pathways such as hyperglycemic toxicity, mitochondrial dysfunction, accumulation of advanced glycation end products (AGEs), and chronic inflammation. Current research faces core challenges, including preclinical models that fail to replicate the progressive nature of human disease, a lack of biomarkers predicting clinical endpoints, and inadequate systems for evaluating drug efficacy. There is an urgent need for an innovative platform that integrates multidimensional target validation and translational research.
Our Diabetic Cardiovascular Complications R&D Services
Ace Therapeutics leverages its multidisciplinary team and advanced platforms to provide tailored support and end-to-end services for diabetes-related cardiovascular complications programs.
To address core pathologies in diabetes such as vascular endothelial injury, myocardial remodeling, and oxidative stress imbalance, we integrate cutting-edge technologies including single-cell sequencing and protein-protein interaction analysis to establish a multidimensional mechanistic investigation system for the precise identification of disease-driving targets.
- Multi-omics-driven target identification: Systematically identify key pathways in myocardial cell apoptosis, vascular endothelial dysfunction, and fibrosis through spatial transcriptomics, proteomics, and metabolomics technologies.
- Customized cell model: High glucose or palmitate-induced cardiomyocyte injury model, human iPSC-derived cell co-culture model.
- Molecular mechanism validation: Focusing on core mechanisms including oxidative stress (ROS), inflammatory signaling (NF-κB, NLRP3), and energy metabolism reprogramming.
Leveraging our SPF-level animal research center, we have established a diverse repository of disease models. These validated diabetic cardiovascular disease models are designed to meet a wide range of client R&D needs, including drug screening, efficacy evaluation, and safety assessment.
- Dual metabolic-cardiovascular phenotype model: db/db mice + ApoE⁻/⁻ hybrid model (Atherosclerosis Research), high-fat diet + low-dose STZ-induced T2DM cardiovascular disease model
- Multi-phenotype validation system:
- Functional assessments: Echocardiography, hemodynamics, vascular reactivity, cardiac index measurement, blood biochemical analysis
- Histological analyses: Myocardial fibrosis staining, arterial plaque analysis, ultrastructural analysis via electron microscopy
Focusing on diverse therapeutic modalities including small molecule drugs, biologics, and cell therapies, we provide end-to-end services from candidate compound screening to preclinical efficacy validation to accelerate the translation of therapies into clinical stages.
- High-throughput screening: Cell/molecular target-based compound library screening.
- Pharmacodynamic evaluation: Core indicator assessments including cardiac function improvement, blood glucose regulation, and vascular protection.
- Mechanism of action clarification: Verification of the compound's regulatory effects on target pathways.
- Pharmacokinetic/Toxicological assessment: Evaluation of drug metabolism characteristics and organ safety under diabetic conditions.
We integrate animal biospecimen resources, detection technologies, and bioinformatics analysis to develop biomarkers and diagnostic reagents for the early screening, prognostic assessment, and treatment efficacy monitoring of diabetic cardiovascular disease.
- Biomarker discovery: Multi-omics analysis of biospecimens (screening for miRNA, protein, and metabolite biomarkers).
- Biomarker verification: Validation of specificity and sensitivity using animal models.
- Diagnostic assay development: Development of colloidal gold test strips, chemiluminescence kits, and PCR detection reagents.
- Methodological validation: Testing of precision, accuracy, stability, and other key performance indicators.
- Companion diagnostic Development: Development of companion diagnostic tools integrated with drug R&D and treatment efficacy monitoring.
Advanced R&D Platform for Diabetes and Cardiovascular Complications
High-Throughput Omics Platform
Integrating genomic, transcriptomic, proteomic, and metabolomic data to comprehensively analyze pathological mechanisms and biomarker networks for cardiovascular function assessment.
Organoid Technology Platform
iPSC-derived cardiomyocyte and vascular organoids more closely mimic human physiological and pathological characteristics, enhancing the success rate of preclinical drug development.
Cardiovascular Function Assessment Platform
Equipped with echocardiography, ambulatory blood pressure monitoring, and heart rate variability analysis systems to deliver objective quantitative readings.
Histopathology Platform
Precise quantification of tissue lesions and molecular alterations in diabetic complications, delivering reliable histopathological endpoints for robust efficacy evaluation.
Ace Therapeutics' expert team leverages extensive preclinical experience to provide end-to-end services from mechanism investigation to therapy and diagnostic development. We tailor our services to align with your specific research stage. Contact us today to explore tailored solutions for diabetic and its cardiovascular complications.
All of our services and
products are intended for preclinical research use only and cannot be used to diagnose, treat or
manage patients.
Related Services
Related Products
